Table 2 Cure rates (CR), extended CRs egg-reduction rates (ERR), extended ERRs and reinfection data for the four different treatments against A. lumbricoides infections. Results of baseline and 3Â weeks follow-up have been reported elsewhere [13]
Ascaris lumbricoides | |||||
|---|---|---|---|---|---|
|  | Weeks post-treatment | Albendazole – ivermectin (n = 100) | Albendazole – mebendazole (n = 101) | Albendazole – oxantel pamoate (n = 100) | Mebendazole (n = 104) |
Children positive before treatment (%) | 46 (46.0) | 36 (35.6) | 44 (44.0) | 43 (41.3) | |
No. of children cured (CR, 95 % CI) | 3 weeks | 45 (97.8, 88.5–99.9) | 36 (100, 90.3–100.0) | 43 (97.7, 88.0–99.9) | 41 (95.4, 84.2–99.4) |
No. of children negative (extended CR, 95 % CI) | 18 weeks | 32 (69.6, 54.2–82.3) | 25 (69.4, 51.9–83.7) | 27 (61.4, 45.5–75.6) | 26 (60.5, 44.4–75.0) |
Geometric mean: EPG | Baseline | 2,385.8 | 1,195.3 | 1,503.4 | 1,095.2 |
3Â weeks | 0.1 | 0.0 | 0.2 | 0.4 | |
18Â weeks | 6.9 | 9.1 | 12.5 | 10.6 | |
ERR (95 % CI) | 3 weeks | 99.9 (99.9–100.0) | 100 (−) | 99.9 (99.9–100) | 99.9 (99.8–100) |
Extended ERR (95 % CI) | 18 weeks | 99.7 (99.1–99.9) | 99.2 (97.5–99.8)a | 99.2 (97.1–99.8)a | 99.0 (97.7–99.6)a |
No. of children positive (prevalence, 95 % CI) | Baseline | 46 (46.0, 36.1–55.9) | 36 (35.6, 26.1–45.1) | 44 (44.0, 34.1–53.9) | 43 (41.3, 31.7–51.0) |
3 weeks | 1 (1.0, −1.0–3.0) | 2 (2.0, −0.8–4.7) | 3 (3.0, −0.4–6.4) | 2 (2.0, −0.8–4.6) | |
18 weeks | 24 (24.0, 15.5–32.5) | 28 (27.7, 18.8–36.6) | 33 (33.0, 23.6–42.4) | 33 (31.7, 22.6–40.8) | |
Reinfections (%, 95 % CI) | 18 weeks | 14/45 (31.1, 18.2–46.6) | 11/36 (30.6, 16.3–48.1) | 16/43 (37.2, 23.0–53.3) | 16/41 (39.0, 24.2–55.5) |
New infections (%, 95 % CI) | 18 weeks | 10/54 (18.5, 9.3–31.4) | 17/63 (27.0, 16.6–39.7) | 15/54 (27.8, 16.5–41.6) | 16/61 (26.2, 15.8–39.1) |